Orphazyme gets investor backing for fundraising round
Danish biotech company Orphazyme has received support for its plan to raise new funds after setbacks in 2021.
by victor emil kristensen, translated by catherine brett
Biotech company Orphazyme needs more funds to get its drug candidate arimoclomol to market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma poaches Orphazyme CEO
For subscribers
Orphazyme plans to resubmit FDA application in H2
For subscribers
Orphazyme upgrades after careful spending year
For subscribers
